China

The acquisition encompasses MDCO’s complete portfolio of ophthalmic devices, including intraocular lenses (IOL), implantable contact lenses (Phakic Lens), and various refractive device platforms.

CSPC is expected to receive an additional USD3.5 billion if the programs successfully meet development and regulatory milestones, in addition to royalties from any drugs approved under the partnership.

Kenmare Bio will obtain worldwide development and commercialization rights to an experimental oral small molecule known as FHND5032, with the exception of Greater China, where Chia Tai Feng Hai will retain control.

The investment will enhance AstraZeneca’s existing manufacturing sites in Wuxi, Beijing, Qingdao, and Taizhou, which already serve patients in China and across 70 international markets.

The partnership between these companies stems from a late 2024 licensing agreement in which Corxel obtained worldwide rights to CX11, excluding China, from Vincentage.

AbelZeta will receive up to USD630 million from AstraZeneca, with the payment structure including both upfront cash and milestone fees tied to the GPC3 program’s progress in China.

The NMPA based its decision on compelling evidence from the TRIDENT-1 study, a pivotal Phase I/II clinical trial that demonstrated the drug’s effectiveness over time.

Everest Medicines plans to deliver predictable near-term value through commercializing existing assets, forming business development partnerships, and achieving in-house research and development milestones.

The collaboration is designed to strengthen Everest’s commercial operations in China while expanding its presence in the cardiovascular disease market.